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Abstract
Background: Of the diverse subtypes of Human Immunodeficiency Virus Type-1 (HIV-1), subtype-C strains cause a large
majority of infections worldwide. The reasons for the global dominance of HIV-1 subtype-C infections are not completely
understood. Tat, being critical for viral infectivity and pathogenesis, may differentially modulate pathogenic properties of the viral
subtypes. Biochemical studies on Tat are hampered by the limitations of the current purification protocols. Tat purified using
standard protocols often is competent for transactivation activity but defective for a variety of other biological functions.
Keeping this limitation in view, we developed an efficient protein purification strategy for Tat.
Results: Tat proteins obtained using the novel strategy described here were free of contaminants and retained biological
functions as evaluated in a range of assays including the induction of cytokines, upregulation of chemokine coreceptor,
transactivation of the viral promoter and rescue of a Tat-defective virus. Given the highly unstable nature of Tat, we evaluated
the effect of the storage conditions on the biological function of Tat following purification. Tat stored in a lyophilized form
retained complete biological activity regardless of the storage temperature. To understand if variations in the primary structure
of Tat could influence the secondary structure of the protein and consequently its biological functions, we determined the CD
spectra of subtype-C and -B Tat proteins. We demonstrate that subtype-C Tat may have a relatively higher ordered structure
and be less flexible than subtype-B Tat. We show that subtype-C Tat as a protein, but not as a DNA expression vector, was
consistently inferior to subtype-B Tat in a variety of biological assays. Furthermore, using ELISA, we evaluated the anti-Tat
antibody titers in a large number of primary clinical samples (n = 200) collected from all four southern Indian states. Our analysis
of the Indian populations demonstrated that Tat is non-immunodominant and that a large variation exists in the antigen-specific
antibody titers.
Conclusion: Our report not only describes a simple protein purification strategy for Tat but also demonstrates important
structural and functional differences between subtype-B and -C Tat proteins. Furthermore, this is the first report of protein
purification and characterization of subtype-C Tat.
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Background
Human Immunodeficiency Virus type-1 (HIV-1) exhibits
high levels of genetic variation based on which the viral
strains are classified into several distinct subtypes desig-
nated A through J [1]. Distribution of viral subtypes across
the globe is non-uniform. Additionally, epidemic out-
breaks due to recombinant forms of the viruses are also
increasingly becoming a concern for global infections. Of
the various subtypes, subtype-C has been successful in
establishing rapidly growing epidemics in the most popu-
lous nations of Sub-Saharan Africa, Asia including India
and China and Latin American countries like Brazil. Glo-
bally, subtype-C strains are responsible for nearly 56% of
the infections [2]. The recent data emerging especially
from southern Brazil [3] allude to proliferation profi-
ciency of subtype-C viruses and such differences might
partly be attributed to biological properties unique for
this particular viral subtype. Although subtype-C viruses
alone cause more infections than all other subtypes com-
bined, relatively little is understood of their molecular
and pathogenic properties. The current knowledge of HIV-
1 pathogenesis is derived mostly from studies on subtype-
B strains that have been prevalent in the US and Europe
[4]. Whether the various genetic subtypes and recom-
binant forms of HIV-1 have biological differences with
respect to transmission and disease progression, is contro-
versial [5-8]. Tat, being critical for viral infectivity and
pathogenesis, deserves attention with respect to differen-
tial pathogenic properties of the viral subtypes [9,10].
Tat, a key viral transactivator regulating gene expression
from the viral promoter, is expressed early in the viral life
cycle from the multiply spliced viral transcript [11]. Tat
binds to the transactivation response element (TAR) that
forms a stable RNA stem loop at the 5' end of all the viral
transcripts and recruits pTEFb, consisting of Cyclin T1 and
CDK9, to TAR. Hyper-phosphorylation of the carboxy ter-
minal domain of RNA polymerase II by CDK9 leads to
enhanced elongation of the transcription from the viral
promoter [12,13]. In the presence of Tat, gene expression
from the viral promoter is upregulated several hundred
fold. In addition, Tat is secreted from productively
infected cells into extracellular medium through a poorly
defined pathway [14,15]. The extracellular Tat can reenter
cells through the caveolar pathway [16] interacting with a
variety of cellular receptors on the cell surface including
heparan sulphate proteoglycans [17], and integrin recep-
tors α5β1 and αvβ3 [18]. Extracellular Tat, readily taken
up by cells, could reach the nucleus and modulate the
expression of a variety of cellular genes including
cytokines [19,20], chemokine coreceptors [21,22], MHC
complex [23,24], and many others [25-27] thus contribut-
ing significantly to the overall pathogenicity of the virus.
Given the significant role Tat plays in regulating several
critical viral and cellular properties and the important dif-
ferences in the amino acid residues identified in the Tat
proteins of diverse viral subtypes [9,28,29], a systematic
evaluation of a possible correlation between Tat diversity
and subtype properties is necessary [9,10]. Studies of this
nature, however, require purification of large quantities of
biologically functional Tat protein, which is relatively dif-
ficult to achieve using the existing methodologies. Protein
purification of Tat from a recombinant source, especially
E. coli, is wrought with several technical challenges mainly
because of the intrinsic properties of this viral protein. Tat
contains several functional domains each regulating mul-
tiple and often overlapping and complementary biologi-
cal functions [30]. The presence of charged and
hydrophobic amino acid residues in Tat makes protein
purification difficult as this protein adheres to surfaces.
Additionally, Tat containing a cysteine-rich domain, con-
sisting of 6 or 7 cysteines, is prone to inactivation through
oxidation and/or reduction. Tat also has an intrinsic ten-
dency to multimerize and aggregate on storage and the
multimer forms of Tat are biologically inactive [31].
Several protein purification strategies have been reported
for recombinant Tat. One commonly used strategy is the
expression of Tat with a peptide tag that would facilitate
purification [31-34]. An alternative approach exploits
Tat's natural affinity for heparin [15,35]. Most of the
reported protein purification protocols have been stand-
ardized using Tat derived from a subtype-B source (B-Tat).
Attempts to purify Tat from a subtype-C source (C-Tat), as
well as subtype-B, using the reported protocols presented
two problems. First, the yield was significantly poor and
second, the protein lost its biological properties com-
pletely or partially. C-Tat is characterized by the presence
of several signature amino acid residues [9]. Additionally,
several of the standard protocols involve the use of a
reverse-phase column chromatography for Tat purifica-
tion [33,36-38]. In our hands, the bulk of Tat adhered to
the hydrophobic columns and failed to elute from these
columns resulting in poor protein yield. Moreover, pro-
tein eluted from such columns was often found to be bio-
logically inactive, possibly a result of exposure to harsh
organic solvents, suggesting that reverse-phase column
chromatography might not be an ideal choice for the puri-
fication of a strongly hydrophobic protein like Tat. In view
of these limitations, we developed a simple and efficient
protein purification strategy for Tat that uses in tandem a
Ni-NTA affinity column and an anion-exchange chroma-
tography. We applied this purification strategy to C-Tat, as
well as B-Tat, with high protein yield. A 6-amino acid His-
tag was placed at the C-terminal end of the Tat proteins to
permit Ni-NTA column purification. The protein was
approximately 99% pure and biologically active as evalu-
ated in a range of transactivation assays and signalingRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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events. Here, we report not only a novel and simple pro-
tein purification strategy for Tat but also demonstrate that
transactivation activity alone is not an optimal correlate
for the functional integrity of Tat. Additionally, we dem-
onstrate important differences between B- and C-Tat pro-
teins at biological and structural levels.
Results and discussion
Purification and characterization of the recombinant Tat 
proteins
Although highly conserved within a viral subtype, the
amino acid sequences of Tat are significantly diverse
among viral subtypes. Such variation may underlie impor-
tant biological differences of the viral subtypes. For
instance, a recent study demonstrated natural variation at
position 32 in subtype-E Tat, but not in subtypes B or C,
causing selective inhibition of TNF gene transcription in
Jurkat cells [10]. We previously demonstrated a natural
substitution of a serine residue for a cysteine at position
31 and suggested attenuated chemokine function of sub-
type-C Tat for monocytes [9]. Given that the vast majority
of the global viral infections are ascribed to subtype-C [2]
and that Tat protein is a key viral factor significantly con-
tributing to viral pathogenesis, we wanted to purify Tat
from subtype-C origin for experimental evaluation. Our
initial attempts at purifying Tat from bacterial lysates
using reported protocols not only yielded low quantities
of the protein but also the isolated protein was often com-
pletely or partially inactive.
Importantly, we repeatedly observed that the transactiva-
tion property of Tat was usually not affected by the pro-
tein purification strategy employed. The protein
purification strategy used, however, dramatically affected
many other biological functions of Tat often without
modulating the transactivation property (Figure 1). Tat
proteins purified from subtype-B and -C, using standard
protocols that employ reverse-phase chromatography,
successfully mediated production of a Tat-defective provi-
rus from HLM-1 cells (Figure 1A) suggesting that the pro-
Discordance between the Transactivation and cytokine induction functions of Tat Figure 1
Discordance between the Transactivation and cytokine induction functions of Tat. (A) Rescue of the Tat-defective provirus. 
HLM-1 cells harbor an integrated provirus defective for Tat and produce large quantities of virus when complemented with a 
functional Tat protein. HLM-1 cells were incubated with B- or C-Tat (5 μg/ml) in complete medium or without Tat. Following 
Tat transfection, culture medium was collected at 24, 48 and 72 h and the levels of the viral structural protein, p24, secrerted 
into the medium was estimated using an antigen – capture assay. Data for the 72 h time point are presented here. Tat proteins 
(from subtypes -B and C) synthesized using a previously reporetd protocol were competent for the transactivation property. 
Tat proteins prepared using the protocol described in the present report were also transactivation competent (data not pre-
sented) (B) Induction of TNF-α secretion from primary monocytes. B- and C-Tat proteins prepared as above and as described 
in the present report were included for a comparative analysis. Monocytes freshly isolated from peripheral blood were incu-
bated with the Tat proteins at two different concentrations (20 or 200 ng/ml) for 30 or 60 min. Cells were washed three times 
to remove Tat, resuspended in complete medium and incubated for 24 h. The amount of TNF-α secreted into the culture 
medium was assessed using a commericial kit following the manufacturer's instructions (R&D Systems). Tat proteins prepared 
using the protocol reported in the present manuscript successfully induced cytokine production from the monocytes in a dose-
dependent manner. In contrast, Tat proteins prepared using reverse-phase chromatography failed in the induction. Note that 
the same Tat proteins were transactivation-competent and activated expression of a Tat-defective provirus (panel A above) 
and reporter genes under the viral LTR (data not presented).
A.Viral proliferation B. TNF-α induction
B-Tat C-Tat No Tat
p
2
4
(
n
g
/
m
l
)
0.0
0.5
1.0
1.5
20 200 20 200
B-Tat C-Tat No Tat
T
N
F
-
α
 
(
n
g
/
m
l
)
Conc. of Tat ( ng/ml )
0.0
2.0
4.0
6.0
Present method
Previous methodRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
Page 4 of 20
(page number not for citation purposes)
tein was capable of entering the cell and transactivating
the viral promoter. These Tat proteins, however, failed to
induce the secretion of TNF-α from monocytes (Figure
1B). In contrast, Tat proteins purified using the strategy
reported here were competent for both transactivation
and signaling properties (Figure 1B and see later).
In view of these limitations, we developed the present
protein purification strategy for Tat without the use of the
reverse-phase chromatography procedure. The protein
purification strategy, as schematically depicted in Figure 2,
consists of an affinity chromatography and an ion-
exchange column chromatography, performed sequen-
tially in that order. We amplified full-length Tat (101 res-
idues) from an Indian subtype-C clinical sample, cloned
it into a bacterial expression vector under the control of a
T7 promoter and added a His-tag of 6 amino acid residues
to the C-terminus of Tat to facilitate purification via Ni-
NTA chromatography [39]. Tat protein eluted from the
Ni-NTA columns was relatively pure and free of bulk of
the bacterial proteins as assessed by SDS-PAGE electro-
phoresis (Figure 3A, lane 5). We found trace amounts of
additional protein bands in this lane that are partly host
proteins, partly Tat multimers (slow moving bands) and
Tat degradation products (rapidly moving bands) as ana-
lyzed using Western blot (results not presented).
Tat protein eluted from Ni-NTA was directly applied to an
anion-exchange column without removing imidazole.
The isoelectric point (pI) of most of the Tat proteins is
slightly alkaline (around pH 8 or above), whereas that of
most of the E. coli host proteins is acidic, below pH 6 [40].
We took advantage of the difference in the pI values of Tat
and E. coli host proteins and employed an anion-exchange
chromatography in the purification strategy. At pH 6.8,
where Tat was applied to the column, Tat was positively
charged whereas E. coli proteins were expected to be neg-
atively charged. Tat eluted from the Ni-NTA columns con-
tained 300 mM Imidazole. Presence of imidazole at such
a high concentration did not interfere with binding of Tat
to the ion-exchange column. Tat eluted from the ion-
exchange column is nearly free of bacterial proteins (Fig-
ure 3A, lane 7). Trace levels of additional protein bands
above and below the main Tat band are multimers and
degraded protein products of Tat, respectively, as seen in
Western blot (data not presented). Thus, application of
the Ni-NTA column chromatography and the ion-
exchange chromatography, in tandem, not only efficiently
removed E. coli proteins from Tat but also eliminated imi-
dazole from the protein.
One serious limitation to recombinant protein expression
in E. coli is the copurification of lipopolysaccharides (LPS)
or endotoxin with the protein. LPS is the constituent com-
ponent of Gram negative bacterial cell walls [41]. Endo-
toxins are negatively charged and copurify with similarly
charged proteins like Tat. Even trace quantities of residual
endotoxin could be highly toxic to the cells and tissues of
mammalian origin especially those of human [42]. LPS
could induce profound effects on mammalian cells, by
engaging specific receptors on monocytes, macrophages
and cells of other lineages and cause cell maturation,
upregulation of costimulatory molecules, and release of
several potent cytokines, prostaglandins, interleukins and
platelet activating factors. Tat itself is known to induce
secretion of several cytokines of immunologic significance
from host cells [19,43,44]. Therefore, it is essential to
remove endotoxin completely from Tat expressed from a
bacterial source. We used Triton X-100 at 2% concentra-
tion to extensively wash the columns as Tat was immobi-
lized on the columns. Above a critical concentration of the
detergent, the lipid A component of endotoxins interacts
with the micellar structures of the detergent and as a con-
sequence of this interaction, endotoxins are efficiently
separated from the aqueous phase [45,46]. Washing the
Schematic representation of isolation and purification of the  Tat protein Figure 2
Schematic representation of isolation and purification of the 
Tat protein.
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( Buffer with 2% Triton X-100 )
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columns with 2% Triton X-100, while Tat is bound on the
columns, resulted in a reduction of endotoxin levels in the
eluted Tat to the order of approximately 500 and 9,000
times after Ni-NTA and ion-exchange chromatographies,
respectively (Table-1). The final concentration of endo-
toxin in the eluted Tat was approximately 0.04 EU/μg of
protein which is within the acceptable limit [47]. The
acceptable level of endotoxin for intravenous injections of
plasmid DNA is 0.1 EU/μg [47] and 5 EU per KG weight
of the recipient for recombinant proteins [46]. The pres-
ence of Tat was confirmed in Western blot using a Tat spe-
cific monoclonal antibody (Figure 3A) and the purity of
the protein confirmed using MALDI-TOF (Figure 3B). The
mass spectrum of C-Tat revealed a single major peak with
a mass of 12513.317 as compared to the calculated mass
of 12274.67 for a monomer. Tat degradation products
were seen as minor low mass compounds and a Tat dimer
at 25210.273. This analysis as well as the Western blot
identified that the large proportion of Tat purified using
the strategy reported here is a monomer with minor deg-
radation products and a few multimers. We obtained
essentially identical results with B-Tat purification. The
Purification and biochemical characterization of recombinantly expressed subtype-C Tat protein Figure 3
Purification and biochemical characterization of recombinantly expressed subtype-C Tat protein: (A) SDS-PAGE and Western 
blot analyses of the purified Tat protein. E. coli cells expressing Tat were harvested by centrifugation and lysed by sonication. 
Bacterial lysate was subjected to two successive strategies of protein purification, Ni-NTA and SP-Sepharose chromatogra-
phies. Measured quantity of the protein from different elutes was resolved on a 15% SDS-PAGE gel, M, protein molecular 
weight standards (# M3913, Sigma, St. Louis, Missouri, USA). Bottom pannel shows Western blot analysis of the Tat protein 
resolved on a duplicate SDS-PAGE gel and electrophoretically transferred to a PVDF membrane. A Tat-specific monoclonal 
antibody (# 4138, NIH AIDS Research and Reference Reagent Program) was used for the Western blot. (B) MALDI-TOF 
spectrum of the purified Tat protein. Purified and lyophilized Tat protein was reconstituted in sterile distilled water and sub-
jected to MALDI-TOF analysis. (C) CD spectra of B-Tat and C-Tat were measured from 250 to 190 nm with a 0.1 cm path 
length in 10 mM phosphate buffer (pH 7.0).
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SDS-PAGE, Western blot and MALDI-TOF profiles of B-
Tat are presented in the figure 4.
X-ray crystallographic information on Tat is lacking. Tat,
like several other transactivation factors, is highly flexible
and lacks well-structured three-dimensional folds [48,49].
Circular dichroism (CD) analyses of Tat derived from sub-
types -B and -D in aqueous solutions identified primarily
random coil structures and/or α-turns [50]. Importantly,
minor structural variations in Tat are implied to influence
the pathogenic properties of the viral protein [28]. Exon-
1 of subtype-C Tat is characterized by a minimum of 6 sig-
Purification and biochemical characterization of recombinantly expressed subtype-B Tat protein Figure 4
Purification and biochemical characterization of recombinantly expressed subtype-B Tat protein: (A) SDS-PAGE and Western 
blot analyses of the purified Tat protein. Tat expression cassette was amplified from a standard HIV-1 subtype B molecular 
clone, YU-2, and subcloned into a bacterial expression vector. E. coli cells expressing Tat were harvested by centrifugation and 
lysed by sonication. Bacterial lysate was subjected to two successive strategies of protein purification, Ni-NTA and SP-Sepha-
rose chromatographies. Measured quantity of the protein was resolved on a 15% SDS-PAGE gel, M, protein molecular weight 
standards (# M3913, Sigma, St. Louis, Missouri, USA). Bottom pannel shows Western blot analysis of the Tat protein resolved 
on a duplicate SDS-PAGE gel and electrophoretically transferred to a PVDF membrane. A Tat-specific monoclonal antibody (# 
4138, NIH AIDS Research and Reference Reagent Program) was used for the Western blot. (B) MALDI-TOF spectrum of the 
purified Tat protein. Purified and lyophilized Tat protein was reconstituted in sterile distilled water and subjected to MALDI-
TOF analysis.
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Table 1: Recovery of Tat protein and removal of endotoxin
Tat Sample Endotoxin (EU/μg) Yield (mg/Liter)
B-Tat C-Tat B-Tat C-Tat
Neat E. coli lysate 340 320 - -
Ni-NTA (without Triton 
wash)
7.6 5.5 3.0 5.0
Ni-NTA (after Triton 
wash)
0.75 0.55 2.0 4.0
After SP-Sepharose 0.039 0.034 0.5 1.0
Tat protein recombinantly expressed in bacteria was purified using Ni-NTA column chromatography and ion-exchange column chromatography 
performed sequentially. Protein concentration of the eluted Tat protein was determined using a dye binding assay [99]. Endotoxin concentration in 
the samples was determined using a commercial kit (QCL-1000, Biowhittaker).Retrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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nature amino acid residues [9]. To understand if amino
acid variation between B- and C-Tat proteins could influ-
ence the secondary structure of the proteins and conse-
quently their biological functions, we measured the CD
spectra of C-Tat from 190 to 250 nm with a 0.1 cm path
length in an aqueous buffer (Figure 3C). For comparison,
Tat isolated from YU-2, a subtype-B molecular clone [51],
was also included in the analysis. With B-Tat, as reported
previously [52], we observed a negative band at 208 nM,
typical of non-organized structures. Analysis of C-Tat, on
the other hand, revealed two important differences. First,
the negative band for C-Tat appeared at 204 nM, shifted
from 208 nM of B-Tat. Second, the intensity of the nega-
tive band of C-Tat, as compared to B-Tat, was of lesser
magnitude suggesting that C-Tat possibly might have a
relatively higher ordered structure and be less flexible. The
present study is the first report of the CD profile of sub-
type-C Tat protein. The results of the CD profile suggested
that subtype-C Tat might be structurally different from
subtype-B Tat. To understand the differences between C-
Tat and other Tat proteins of other subtypes high resolu-
tion structures of nuclear magnetic resonance are needed.
Recombinant Tat proteins are transactivation competent
Recombinantly expressed Tat is liable to inactivation by
different mechanisms. Most of the previously published
Tat purification protocols used the transactivation prop-
erty of Tat alone to confirm functional integrity of Tat
[15,31,53-55]. We, however, repeatedly observed that Tat
protein purified using protocols published previously
promoted expression of a reporter gene efficiently under
the control of LTR or complemented replication of a Tat-
defective provirus but failed to induce cytokine expression
from primary monocytes or THP-1, a human acute mono-
cytic leukemia cell line (Figure 1). Importantly, recom-
binant Tat protein obtained from reliable sources such as
The NIH AIDS Research and Reference Reagent Program
was also found to be defective in the non-transactivation
properties of Tat (data not presented) underlining the
importance of confirming the biological function of Tat
using more than one property. Keeping this limitation in
view, we simultaneously monitored two or more diverse
and independent functions of Tat, the transactivation
property, the cytokine induction and the coreceptor
upregulation to confirm the functional integrity of the
purified recombinant proteins.
Tat is believed to be secreted into extracellular spaces from
infected cells, cross cell and nuclear membranes of the
neighboring cells efficiently and transactivate latent viral
promoter thus enhancing viral infectivity [14,56]. We
tested the potential of the recombinant Tat proteins puri-
fied using the strategy reported here to enter the target
cells and cause transactivation of the reporter genes under
the control of the viral promoter. HEK293 cells were tran-
siently transfected with a plasmid vector containing green
fluorescent protein (GFP) under the control of the sub-
type-C LTR (C-LTR) and incubated for twenty four hours.
Following the transfection, cells were incubated with B- or
C-Tat proteins (5 μg/ml) for additional 24 hours and the
expression of GFP was documented. Cells incubated with
B- or C-Tat proteins expressed high quantities of GFP (Fig-
ure 5A, top panel). In contrast, cells transfected with the
reporter vector but not exposed to Tat expressed low level
GFP mainly as a result of Tat-independent transactivation
from the LTR (Figure 5A). The reporter gene was placed
under the regulatory control of a subtype-C LTR. Rela-
tively high level basal transactivation was reported from
C-LTR mainly as a consequence of subtype-specific differ-
ences in the regulatory motifs. Subtype-C LTR for instance
contains one or more additional κB binding elements
[57,58] as a result of which C-LTR is believed to be tran-
scriptionally more active in the absence of Tat [59-61].
Regardless of the higher basal level gene expression, the
GFP expression in HEK293 cells was significantly higher
in the presence of Tat suggesting efficient Tat-transactiva-
tion by both the Tat proteins (Figure 5A). Higher levels of
Tat-independent LTR transactivation, however, did not
seem to be a problem when we used a different cell line
CEM-GFP, a T-cell line stably transduced with a GFP
reporter under the control of the HIV-1 LTR (Figure 5A,
lower panel). We have analyzed and recorded GFP expres-
sion at several time points during the course of the exper-
iment, typically at 24, 48 and 72 h. The data shown are
from the 48 h time point. We observed identical reporter
profiles at other time points.
To obtain quantitative information, we repeated the
experiment with a vector expressing secreted alkaline
phosphatase (SEAP) under the control of C-LTR. Culture
supernatants were collected 24, 48 and 72 h after Tat incu-
bation and levels of SEAP in the spent media were deter-
mined using a colorimetric assay. Both the Tat proteins
induced expression of SEAP from the reporter vector in a
time-dependent manner (Figure 5B). Interestingly, in
both the reporter assays, B-Tat upregulated higher levels of
protein expression as compared to C-Tat which was statis-
tically significant by Student's paired t-test (p < 0.001). To
confirm this observation, we transfected CEM-GFP cells
with B- or C-Tat proteins and the GFP expression was eval-
uated by flow cytometry at 24 and 48 h following transfec-
tion. A significantly larger number of cells expressed GFP
when transfected with B-Tat (30.1 and 39.2% at 24 and 48
h, respectively) as compared to C-Tat (18.7 and 24.6% at
24 and 48 h, respectively) while only a smaller fraction of
the control cells were GFP positive (Figure 5C). The above
experiments were repeated several times with different
batches and different concentrations of the Tat proteins.
B-Tat consistantly proved superior to C-Tat in these assays.
Furthermore, we examined Tat-induced virion productionRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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Evaluation of the transactivation property of the Tat proteins Figure 5
Evaluation of the transactivation property of the Tat proteins. (A) HEK293 cells (top panel) seeded in 12-well plates were tran-
siently transfected with 0.5 μg of LTR-GFP reporter vector using a standard calcium phosphate protocol. Cells transfected 
with a blank plasmid were included as a negative control. LTR represents a full-length viral promotor cloned from an Indian pri-
mary subtype-C clinical isolate. Twenty four hours after the transfection, cells were incubated with freshly reconstituted Tat 
protein at a final concentration of 5 μg/ml in complete medium. Twenty four hours following the protein transfection, expres-
sion of GFP was documented using the UV-fluorescence microscopy. CEM-GFP cells (bottom panel), containing a stably inte-
grated GFP gene under the control of subtype-B LTR, were transfected with 5 μg/ml of B or C-Tat proteins using a commercial 
lipid formulation following the directions of the manufacturer (Bioporter, Gene therapy systems, San Diego, CA, USA). or (B) 
HEK293 cells were transfected with a different reporter vector pLTR-SEAP and treated with Tat as described above. Expres-
sion of alkaline phosphate secreted into the medium was estimated at 24, 48 and 72 h using a colorimetric assay. The difference 
between B- and C-Tat treatments at all the time points was found to be statistically significant by Student's paired t-test. The p 
value at 72 h is shown. (C) CEM-GFP cells were treated with 5 μg/ml of B- or C-Tat proteins for the duration shown or left 
without treatment. Cells were harvested, fixed with 2% formaldehyde and evaluated for GFP expression using FACSCalibur 
flow cytometer (BD Biosciences). The live cells were gated on the basis of forward and side scatter. The number of GFP posi-
tive cells was determined by using scattergram of side scatter versus FL-1. Cells with fluorescence intensity greater than 101 
were considered to be GFP positive and the gating was done accordingly. A total of 10,000 events were scored. The x-axis 
represents GFP intensity (FL-1) and the y-axis percentage of positive cells. Percent positive cells for the reporter protein are 
shown. The differences between B- and C-Tat treatments at both the time points were found to be statistically significant by 
Student's paired t-test. The p values at 24 and 48 h are < 0.0052* and < 0.0025**, respectively. (D) Rescue of a Tat-defective 
provirus. HLM-1 cells harboring an integrated provirus defective for Tat produce large quantities of virus when complemented 
with functional Tat protein. The cells were incubated with the Tat protein (5 μg/ml) in complete medium and 24, 48 and 72 h 
after Tat-transfection, the viral structural protein , p24, secreted into the culture medium was estimated using an antigen-cap-
ture assay. The difference between B- and C-Tat treatments at all the time points was found to be statistically significant by 
Student's paired t-test. The p value at 72 h is shown. (E) HEK293 cells were cotransfected with 0.5 μg of LTR-SEAP reporter 
vector and 0.1 μg of B-, C-Tat or empty vector. Alkaline phosphatase secreted into the medium was quantified at different time 
points as shown. All the above experiments were repeated several times and the data presented are representative of these 
experiments. CMV-β-galactosidase vector was used in all the transfections to control for differences in the transfection effi-
ciency. β-galactosidase levels in the cell extracts were quantified using a colorimetric assay. All the quantitative assays were 
performed in triplicates and the data are presented as mean of triplicate values ± 1 S.D. The difference between B- and C-Tat 
treatments was not found to be statistically significant by Student's paired t-test. The p value at 72 h is shown.
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from HLM-1 cells that contain a single copy of a Tat-defec-
tive provirus. Cells were incubated with 5 μg/ml of B- or
C-Tat protein and the concentration of the viral antigen,
p24, secreted into the medium was quantified using an
antigen capture ELISA (Perkin Elmer Life Sciences, Bos-
ton, MA, USA). Both B- and C-Tat proteins entered the
cells and complemented the defective provirus. Consist-
ent with other assays, B-Tat released higher quantities of
p24 into the medium at all the time points as compared
to C-Tat and this difference was statistically significant, p
< 0.005 (Figure 5D).
As mentioned above, we repeatedly noticed that C-Tat, as
a protein, was found to induce relatively low level viral
and reporter protein expression from both subtype-B and
-C promoters in comparison with B-Tat (Figure 5A, B, C
and 5D). In contrast, when delivered as a DNA expression
vector (Figure 5E), C-Tat performed consistantly as effi-
ciently as or even superior to B-Tat in transactivating the
LTR (compare Figure 5B and 5E). The difference between
B- and C-Tat DNA expression vectors was not found to be
statistically significant (p = 0.103), the difference between
Tat treatment and the controls, however, was found to be
significant at all the time points. Carefully controlled
experiments ruled out the possibility of differences in pro-
tein concentration, quality and conformation as a possi-
ble explanation for the observed differences between
these two extracellular Tat proteins. It is possible that C-
Tat is relatively less efficient than B-Tat in crossing cell
membranes and we are presently evaluating this possibil-
ity. Our previous work identified several signature amino
acid residues within C-Tat and such variations could dif-
ferentially modulate biological properties of Tat [9].
Importantly, the arginine-glycine-aspartic acid (RGD)
motif present in exon-2 is necessary for Tat to attach to the
integrin receptors α5β1 and αvβ3 on the cell surface and
enter the cells of diverse lineage including monocyte, T
lymphocyte, vascular and skeletal muscle cells [62,63]. Tat
binds these cells in a dose-dependent manner using the
RGD motif and Tat mutants lacking the RGD motif fail to
mediate efficient cell adhesion [62]. Interestingly, sub-
type-C Tat protein is naturally devoid of the RGD motif
[1] and absence of this motif may adversely affect cell
attachment of C-Tat and the subsequent internalization.
We are presently comparing additional Tat clones from
subtype-B and -C primary clinical isolates to confirm this
observation.
Recombinant Tat proteins mediate cytokine secretion and 
coreceptor upregulation
Extracellular Tat could contribute to viral pathogenesis by
several different mechanisms [43,64-66] including activa-
tion of host cells to secrete cytokines and other immuno-
logically potent molecules [44]. Cytokines secreted by
host cells could further contribute to immune dysfunction
manifested in AIDS [67]. Tat can drive transcription of a
number of cytokine genes from cells of different lineage
including monocytes, astrocytes, B-cells and T-cells [68].
Although the actual mechanism by which Tat induces
cytokine secretion from the host cells is not completely
understood, for some cytokines, engagement of specific
receptor(s) on the cell surface appears to be necessary.
Transient exposure of monocytes or astrocytes to Tat for
periods as brief as 5 min is sufficient to induce secretion
of cytokines from these cells for extended periods.
Involvement of two different signaling pathways, the PKC
pathway and the calcium pathway, could stimulate
cytokine secretion from cells when exposed to Tat [69].
Additionally, exposure of Tat in the order of only millisec-
onds is sufficient to induce prolonged depolarization in
neurons leading to neurotoxicity [70]. Collectively, these
data suggest that transient and/or prolonged exposure of
the host cells to Tat could result in a cascade of events
leading to cell activation, cytokine secretion and immu-
nomodulation.
Considering the importance of Tat-mediated cytokine
induction for viral pathogenicity, we evaluated gene
expression of two important cytokines, TNF-α and IL-6,
from host cells exposed to recombinant B- or C-Tat pro-
teins. Monocytes were isolated from fresh peripheral
blood by two rounds of differential density gradient cen-
trifugation [71]. A flow cytometric analysis of the mono-
cytes using anti-human CD14 antibody conjugated to
phycoerythrin (PE) identified these cells to be approxi-
mately 86% pure (inset Figure 6A). Monocytes were
exposed to two different concentrations of Tat, 20 and
200 ng/ml, in complete medium for 30 or 60 min. Con-
centration of TNF-α was assessed in the spent media 24 h
after Tat exposure using a commercial antigen capture
assay (R&D Systems, Minneapolis, MN, USA). Both B-
and C-Tat proteins induced high levels of cytokine expres-
sion from monocytes in a dose- and time-dependent man-
ner (Figure 6A). LPS, at a concentration of 1.0 ng/ml, was
used as a positive control for TNF-α secretion from mono-
cytes. Interestingly, B-Tat, as in the transactivation assays,
proved superior to C-Tat in inducing TNF-α secretion
from the host cells although induction of cytokines is
functionally a different assay and probably doesn't require
cellular entry by Tat. To ensure that the trace levels of the
endotoxin present in the protein preparations did not
affect secretion of TNF-α from the cells, we included an
additional control of the HIV-1 structural protein p24.
p24 was isolated essentially using the same protein purifi-
cation strategy as for Tat and contained low levels of endo-
toxin, below the detection limit. The viral structural
protein failed to induce TNF-α from the target cells sug-
gesting that the differential cytokine induction by the two
Tat proteins is probably the result of the intrinsic differ-
ences between these two Tat proteins. Additionally, TatRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
Page 10 of 20
(page number not for citation purposes)
Activation of the cytokine signaling events by the Tat proteins Figure 6
Activation of the cytokine signaling events by the Tat proteins. (A) Secretion of TNF-α from primary monocytes. Monocytes 
were isolated from peripheral blood by differential density gradient centrifugation and seeded in 96-well plates at 1 × 104 cells/
well. The culture medium was supplemented with 20 or 200 ng/ml of B-or C-Tat proteins or left without Tat and incubated for 
30 or 60 min. Cells were washed 3 times to remove Tat, resuspended in complete medium and incubated for 24 h. The level of 
TNF-α secreted into the culture medium was assessed using a commericial kit following the manufacturer's instructions. The 
experiment was repeated three times and the data presented are from one of the representative experiments. The data are 
presented as the mean value of triplicate wells ± 1 S. D. Inset, purity of the monocytes evaluated by flow cytometry. The for-
ward vs. side scatter profile of cells isolated is presented. Approximately 86% of the gated cells are monocytes. The differences 
between B- and C-Tat treatments under all the conditions were found to be statistically significant by Student's paired t-test. 
For instance, at 60 min time point, the p values were < 0.05* for 20 ng and < 0.002** for 200 ng of Tat (B) Upregulation of the 
IL-6 transcript in U373-MAGI cells. U373 MAGI cells were exposed to B- or C-Tat at a concentration of 0.2 or 2 μg/ml or left 
without Tat treatment. Twenty four hours after Tat treatment, cells were lysed by directly adding Trizol to the wells and the 
total cellular RNA was isolated using standard protocols. An RT-PCR (5 ng input RNA) was performed to estimate the levels 
of IL-6 or β-actin transcripts. Amplified DNA fragments were resolved on a 1% agarose gel and visualized by ethidium bromide 
staining. The relative densities of the PCR fragments were determined by scanning the gel on a Phosphor Imager (FLA5000, 
Fuji). The intensity values of IL-6 fragments were normalized against β-actin and the fold upregulation in IL-6 transcript as a 
result of Tat treatment was presented in the bar diagram. (C) Tat-induced upregulation of chemokine receptors on mono-
cytes. Monocytes were stimulated with 100 ng/ml B-, C-Tat proteins or cells were left without Tat treatment. Cells were har-
vested after 72 h, incubated for 20 min with PE conjugated monoclonal antibodies to human CXCR4 (12G5; Pharmingen), or 
CCR5 (2D7; Pharmingen), fixed with 2% formaldehyde and analyzed for coreceptor expression by FACSCalibur flow cytome-
ter. The live cells were gated on the basis of forward and side scatter. Unstained monocytes were used as control. Expression 
of the chemokine receptors was analyzed using histograms with FL-2 on the x-axis and percent positive cells on the y-axis. A 
total of 10,000 events were scored. The differences between controls and Tat treatments were evaluated using Student's 
paired t-test and found to be statistically significant. In the case of CXCR4 upregulation, No Tat vs. B-Tat, p < 0.00004; No Tat 
vs. C-Tat, p < 0.00001; B-Tat vs. C-Tat, *p < 0.184. In the case of CCR5 upregulation, No Tat vs. B-Tat, p < 0.00001; No Tat 
vs. C-Tat, p < 0.001; B-Tat vs. C-Tat, ** p < 0.019.
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proteins boiled for 30 min failed to induce TNF-α
although endotoxins are heat stable (data not presented).
Importantly, the protein solutions (B-Tat, C-Tat and p24)
contained trace levels of endotoxin, below 0.05 EU/μg of
protein that corresponds to 5 pg of endotoxin. Such low
concentration of endotoxin must be too inadequate to be
of functional significance for cytokine induction or other
biological properties. Since the flow cytometric analysis of
the monocyte preparation indicated the presence of cells
of non-monocyte origin, we repeated these experiments
using human monocyte (THP-1) and astrocyte
(U373MG) cell lines. We obtained identical results with
THP-1 cells, as with the primary monocytes, although
overall magnitude of cytokine secretion was lower (data
not shown). We also evaluated the induction of the IL-6
transcript in U373MG cells exposed to B- or C-Tat pro-
teins, using a semi-quantitative RT-PCR. Expression of IL-
6 mRNA was upregulated 2.0 and 3.4 fold with B-Tat and
1.6 and 2.5 fold with C-Tat when the cells were treated
with 0.2 and 2.0 μg/ml of the corresponding Tat protein,
respectively, as compared to the control cells (Figure 6B).
Furthermore, we evaluated the ability of the Tat proteins
to upregulate coreceptor expression on the target cells. Tat
was previously shown to upregulate expression of CXCR4
and CCR5 two fold or more on T-lymphocytes and mono-
cytes and influence viral infectivity [21,22,72,73]. We
exposed freshly isolated monocytes to 100 ng/ml of Tat
for 72 h and evaluated coreceptor expression on these
cells by flow cytometry. While primary monocytes
expressed basal levels of CXCR4 and CCR5 in the absence
of Tat, these levels nearly doubled when the monocytes
were treated with B- or C-Tat proteins (Figure 6C). The dif-
ference in the surface expression levels of CCR5 or CXCR4
with and without Tat treatment was statistically significant
as evaluated by Student's paired t-test (P < 0.0005).
The data obtained from primary monocytes and three dif-
ferent cell lines on the expression pattern of two different
cytokines and chemokine coreceptors collectively proved
that the recombinant Tat proteins isolated from two dif-
ferent viral subtypes are functionally active. We obtained
similar data with the Tat proteins from three other viral
subtypes A, D and E (data not presented). It is important
to note that two different assays we used here to test the
recombinant Tat, transactivation and cytokine induction,
differ from each other with respect to the mode of Tat
interaction with the cell. While in the transactivation
assay, Tat must enter the cell and its nucleus to activate the
viral promoter, for the activation of cytokine secretion a
simple engagement of cell receptors on the membrane is
probably sufficient. Recombinant Tat proteins prepared
from two different viral subtypes (subtype -B and -C)
using the protein purification strategy presented here were
found functionally competent in activating the cell signal-
ing as well as the transactivation events. They not only
crossed cellular and nuclear membranes but also upregu-
lated gene expression from viral promoter derived from
two different viral subtypes (subtype-B and -C).
Low magnitude anti-Tat humoral immune response in the 
sera of HIV-1 infected subjects
To confirm antigenic nature of the recombinant Tat, we
analyzed humoral immune response in subtype-C infec-
tion. In the natural infection, Tat is poorly immunogenic
partly because of its predominantly nuclear localization
and partly because of its small molecular size. Humoral
and cellular immune responses to this viral antigen are
observed only in a small number of seropositive individ-
uals and at a low magnitude when present [74-77].
Importantly, immune responses to Tat, humoral and cell-
mediated immune responses, are inversely correlated to
disease progression and appear to be protective [78-81].
Given the importance of antibody response to Tat, we
evaluated the anti-Tat IgG antibody titers in a large
number of primary clinical samples (n = 200) collected
from all the four southern states of India using an indirect
ELISA format. IgG antibodies directed against gp41 were
also estimated in the same plasma samples using a com-
mercial kit. Unlike Tat, gp41 is immuno-dominant and
strong antibody responses are generated against a highly
conserved epitope [82,83]. Detection of anti-gp41 anti-
bodies in the HIV-seropositive samples serves as an inter-
nal standard to compare the quality of the humoral
immune response against Tat on the one hand and helps
confirm the seropositive status of the samples used in this
study on the other hand. We also included a set of 150
plasma samples collected from healthy seronegative
donors in this analysis.
Our analysis identified a large variation in the Tat-specific
IgG antibody titers in the Indian plasma samples (Figure
7). The median antibody titer 0.335 of the HIV group was
significantly higher than that of the control group with a
median absorbance value of 0.131 (p < 0.001). Impor-
tantly, only a small number of the HIV plasma samples
(18%, 36/200) contained Tat-reactive antibodies above
an arbitrary cut off value of 0.3 absorbance. In contrast, 10
% (15/150) of the control sera exceeded this cut off value
and overlapped significantly with the seropositive group.
Seroreactivity of the control sera can be attributed to the
existence of natural antibodies against Tat [84]. A large
number of the HIV samples of southern India did not con-
tain significant titers of Tat-reactive IgG antibodies con-
firming the previous reports from other populations
demonstrating the non-immunodominant nature of Tat
in the natural infection [74-77,85,86]. The present study
is the first one to analyze anti-Tat IgG antibody titers in
the Indian populations. Anti-gp41 IgG antibody response,
unlike that of Tat, was not only of higher magnitude in
these samples but also the titer variation was narrow con-Retrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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firming the immunodominant nature of this viral antigen.
The median anti-gp41 antibody titer 0.895 was signifi-
cantly higher than that of the control group 0.074 (p <
0.0001) confirming the seronegative status of the control
population. Additionally, none of the control samples
contained significant titers of antibodies to gp41. Addi-
tional analysis of the Tat-reactive antibodies identified an
isotype class switch in all the HIV-1 seropositive plasma
samples that fared above the cut off mark. Interestingly,
isotype switching was not observed in normal sera with
antibody titers above the cut off value (data not pre-
sented). We are presently evaluating the significance of
the isotype switch to Tat neutralization and the relevance
of Tat-reactive antibodies to disease progression in Indian
clinical cohorts.
Stability of the recombinant Tat protein under different 
conditions of storage
Tat, being a protein rich in highly charged and hydropho-
bic amino acid residues, is highly unstable and inappro-
priate storage conditions and handling could significantly
affect its biological functions. The cysteine-rich domain of
Tat contains 6 (subtype-C) or 7 (all other viral subtypes)
highly conserved cysteines. Oxidation as well as reduction
of Tat could lead to inactivation of the viral protein
[49,87]. Additionally, Tat forms dimers and multimers
and experimental evidence suggests that only the mono-
meric form of Tat is biologically active [31]. In view of the
importance of storage and handling of Tat for preserving
its biological functions, we evaluated and optimized these
conditions.
After purification, recombinant Tat was lyophilized and
stored in small aliquots at -70°C. To assess the stability of
Tat, the lyophilized protein was reconstituted in a buff-
ered solution and stored in the presence of 1 mM DTT, at
different temperatures (ambient temperature, 4°C, -
20°C, -70°C) for different time periods (8, 15, 30 and 60
days). Lyophilized Tat aliquots were also incubated along
with the reconstituted protein samples for the same dura-
tion at the defined temperatures. Incubation of Tat for dif-
ferent periods was planned such a way that the harvest of
the samples for the assay converged on the same day. At
the end of the incubation, the physical configuration of
Tat was examined using SDS-PAGE analysis. Additionally,
biological activity of Tat was evaluated using two different
assays, rescue of a Tat-defective virus (the transactivation
property) and induction of TNF-α from the host cells (a
cell signaling function). Multimer forms, dimers and
higher forms, of Tat were seen in all the samples of Tat
regardless of the storage condition and temperature (Fig-
ure 8A). Samples stored at room temperature and 4°C,
formed excess quantities of multimer forms of the protein
(compare lanes 1 and 2 across the panels, Figure 8A).
These high molecular weight bands were visible by day 15
in the sample stored at the room temperature and on day
60, nearly half the total protein was identified in the mul-
timerized form. In contrast, protein samples stored frozen
(at -20°C and -70°C) appeared to be stable and like the
freshly reconstituted sample, they did not form excessive
multimer forms (Figure 8A). Although high mobility pro-
tein bands were seen in these samples, they constituted a
relatively small fraction of the total protein.
Proteins stored at different temperatures for various peri-
ods were tested for their ability to rescue a Tat-defective
provirus from the HLM-1 cells when these cells were incu-
bated in the presence of Tat. Lyophilized Tat, regardless of
the storage temperature, retained full transactivation
activity, efficiently complemented Tat-defect in HLM-1
cells and induced production of large quantities of the
virus from the cells (Figure 8B). Reconstituted protein
stored frozen (at -20°C and -70°C) also retained transac-
tivation activity for 60 days, although the lower tempera-
ture appears to be a better choice for storage. Tat stored at
4°C progressively lost the transactivation property as a
function of time. This protein, however, retained a near
complete activity up to day 8 and approximately 50% of
the activity up to day 15. Tat stored at room temperature
did not show any transactivation property at all. Overall
there appears to be a direct correlation between the phys-
Seroreactivity of the Tat antigen Figure 7
Seroreactivity of the Tat antigen. Determination of Tat and 
gp41-reactive IgG antibody titers in HIV-1 seropositive and 
control plasma samples. Plasma samples were diluted 1:100 
and 1:50 for Tat and gp41 ELISAs, respectively. Each sample 
was tested in triplicate wells and the experiment was per-
formed twice. n, the number of samples included in the 
study; p values and mean absorbance are shown in the box 
plots with the median represented by a horizontal line. The 
cut off value for the assay was indicated by a horizontal line.
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ical form of Tat (monomer vs. multimer) and its transac-
tivation property.
We also simultaneously evaluated the influence of the
storage conditions on the property of Tat to induce
cytokine secretion from host cells. Lyophilized Tat, stored
at different temperatures and freshly reconstituted in a
buffer containing 1 mM DTT, regardless of the storage
temperature, induced high quantities of TNF-α from
human monocytes isolated from fresh blood (Figure 8C).
Interestingly, the cytokine induction property of Tat, as
opposed to the transactivation function of the same prep-
aration, appeared to be more sensitive to the storage tem-
perature of the protein solution. Tat stored even at -70°C
rapidly lost its potential to induce TNF-α with time and
did not contain significant biological activity after day 30.
Tat stored at -20°C showed no significant activity after day
8, while Tat stored at room temperature or at 4°C com-
pletely lacked any potential to induce TNF-α at any time
point. To understand if a correlation existed between Tat
functional activity, especially cytokine induction, and the
redox status of the Tat protein stored in a solution form
for different periods, we used a modified Ellman reaction
[88]. Ellman reagent 5,5-dithiobis (2-nitrobenzoic acid)
reacts exclusively with free sulfhydryl groups in a dose-
dependent manner and releases a yellow product 2-nitro-
5-thiobenzoyate that is measured by colorimetry at 412
nM. Freshly reconstituted Tat was incubated for 60 days at
different temperatures (room temperature, 4°C, -20°C,
and -70°C) in the presence of 0.1 mM DTT. At the end of
the incubation, a fresh vial of Tat was reconstituted and all
the samples were assessed for free sulfhydryl groups in the
Ellman reaction. We identified a direct correlation
between the sulfhydryl content in the Tat solutions and
Infuence of the storage conditions on Tat functional stability Figure 8
Infuence of the storage conditions on Tat functional stability. Freshly reconstituted Tat (in 20 mM Tris, pH 8, and 1 mM DTT) 
was divided into several aliquots and stored at different temperatures (RT, 4°C, -20°C, and -70°C) and incubated for different 
periods (0, 8, 15, 30 and 60 days). As a control, Tat was incubated at these different temperatures in a lyophilized form. (A) 
SDS-PAGE analysis. A portion of the aliquots was mixed with SDS-PAGE buffer, boiled and the samples were resolved on a 
15% SDS-PAGE gel. M, protein molecular weight standards (# SM0431, MBI Fermentas); RT, room temperature. In parallel, 
portions of the same aliquots were used to evulate Tat's potential (B) to stimulate TNF-α production from primay monocytes 
(C) to rescue a defective provirus from HLM-1 cells and (D) to measure free sulfhydryl groups in Tat using DTNB assay. The 
experiment was performed twice and the data presented are from one representative experiment. Data are presented as 
mean value of triplicate wells ± 1 S.D.
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their potential to induce cytokine production (Figure 8D).
The lyophilized Tat and the Tat stored at room tempera-
tures had the highest and lowest absorbance values at 412
nM (0.269 and 0.0134, respectively) with other Tat solu-
tions having intermediary values between these extremes.
The cysteine-rich domain of Tat, containing 6 to 7 highly
conserved cysteines, plays key role in transactivation,
along with the core domain [89,90]. Except cysteine 31,
all the other 6 cysteine residues are indispensable for the
transactivation function [89,91]. A cooperative sharing of
two metal ions among the 6 cysteines and one histidine of
Tat and one cysteine of cyclin T1 is believed to be neces-
sary for the transactivation function of Tat while these two
proteins remain bound to TAR [92]. This model implies
that all the 6 cysteines of Tat must be available in free thiol
form to bind the metal ions, therefore these residues can-
not form disulfide bonds. Experimental evidence, how-
ever, shows that significant proportion of recombinant
Tat in vitro contains monomers that form disulfide bonds
[93]. It is not known which of these two Tat monomers is
biologically functional. For instance, Tat protein stored at
4°C for 8 days lacked both the transactivation (Figure 8B)
and the cytokine induction functions (Figure 8C)
although the monomeric form of Tat clearly constituted
the bulk of the protein (Figure 8A). Based on these data,
we believe that Tat monomer devoid of disulfide bonds is
the biologically active form.
As discussed previously, cytokine secretion from cells, by
and large, is induced by Tat via mechanisms different
from that of transactivation. Tat is believed to engage cer-
tain receptors on the cell membrane and initiate a cascade
of signaling events that ultimately results in the gene
expression of target genes especially those of cytokines
[15,17,63]. The activation of signal transduction is very
rapid, often taking only a few minutes, as internalization
of Tat into the cell probably is not necessary, a process that
would require a few hours [94]. Importantly, the data we
present here demonstrate that Tat depending on its func-
tional integrity may be competent for one but not for a
different kind of biological function. For instance, Tat pro-
tein stored at 4°C for 8 days was capable of rescuing the
provirus from HLM-1 cells through its transactivation
activity (Figure 8B) but the same preparation completely
failed to induce TNF-α from monocytes (Figure 8C)
although this sample did not form multimers at this time
point and most of the protein remained as a monomer.
The data presented here collectively demonstrate the need
for stringent monitoring criteria for Tat biological func-
tions. An enormously large number of biological func-
tions has been ascribed to Tat [30]. Most often only the
transactivation property of Tat is used to test the quality of
Tat. We emphasize that at least one more biological func-
tion of the recombinantly produced Tat must be evalu-
ated. Additionally, evaluation of the redox status of Tat,
using a simple Ellman reaction could also testify to the
functional competence of the Tat preparation.
Conclusion
In summary, we reported a simple and efficient protein
purification strategy for HIV-1 Tat. Using this protocol, we
isolated highly purified Tat from subtypes B and C and
demonstrated important differences in their structural
properties. We have also standardized storage conditions
for Tat and demonstrated the stability profile of Tat under
diverse conditions of storage. Recombinant Tat was trans-
activation active. Furthermore, recombinant Tat success-
fully induced cellular signaling events, induced cytokine
secretion and upregulated coreceptor expression on target
cells. Using recombinant Tat, we identified antigen-spe-
cific antibodies in the Indian patient sera and showed that
Tat is non-immunodominant in subtype-C natural infec-
tion. We also identified important functional differences
between B- and C-Tat when they were delivered as protein
to the target cell.
Methods
Cloning and expression of recombinant Tat proteins
The full-length C-Tat was cloned from a primary Indian
clinical sample and B-Tat from YU-2, a molecular clone of
subtype-B origin. For C-Tat cloning, peripheral blood was
collected from a seropositive donor (BL43/02) and the
mononuclear cells were isolated from the blood using the
density gradient technique. Total RNA was extracted from
the cells using the Trizol reagent (Sigma, St. Louis, Mis-
souri, USA). Tat transcript was reverse transcribed using a
sequence-specific reverse primer (N495: 5'-
GCCCTCTCTCGAGGTCGAAGGGGTCTGTCTC-3'). The
same primer in combination with a forward primer
(N335: 5'-GAGGAGCATATGGAGCCAGTAGATCCTAAC-
3') was used in the polymerase chain reaction to amplify
the Tat gene. Restriction sites engineered into the primers,
XhoI and NdeI, are bolded. The reverse transcription con-
ditions were as follows: 30 min at 42°C and 5 min at
94°C. The amplification reaction mixture of 50 μl con-
tained 250 nM of each primer, 100 μM each deoxynucle-
otide triphosphates, 1.25 U of Taq DNA polymerase, and
3.0 mM MgCl2. Amplification was performed using the
following cycling conditions, pre-amplification denatura-
tion for 30 s at 94°C, followed by 40 cycles, with each
cycle consisting of incubations at 94°C for 30 sec, 60°C
for 30 sec, and 72°C for 30 sec. The amplified product was
purified using a column-based commercial kit (Qiagen,
Hildel, Germany), and cloned directionally between NdeI
and XhoI into a bacterial expression vector pET21b
(Novagen, Madison, MI). As a result of cloning into this
vector, a 6 amino acid His-tag was attached to Tat at the C-
terminal. For subtype-B Tat cloning, HEK293 cells were
transiently transfected with the pYU2 molecular cloneRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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(Cat # M2393, NIH AIDS Research and Reference Reagent
Program) and incubated for 72 h. Extraction of the total
RNA and cDNA preparation were as described above. The
reverse primer (N529: 5'-CTCCACCCTCGAGATGGAC-
CGGATCTGTCTCTGT-3') was used in the reverse tran-
scription reaction. This primer in combination with the
forward primer N335 was used for amplification. The
conditions for amplification and cloning were essentially
as described above. The integrity of all the recombinant
clones was confirmed by DNA sequencing. For the expres-
sion of recombinant Tat proteins, individual bacterial col-
onies (E. coli BL21(DE3)) were grown to 1 liter cultures in
LB medium supplemented with 100 μg/ml ampicillin.
Protein production was induced by adding IPTG to a final
concentration of 1 mM to the cultures at 0.4 OD and incu-
bating the cultures for additional 3 h. The bulk of the Tat
protein was identified in a soluble form. Cells were har-
vested by high-speed centrifugation and resuspended in
20 ml of lysis buffer (20 mM Tris-HCl, pH 7.9; 10% glyc-
erol; 0.4 mM, EDTA; 300 mM KCl; 0.1% IGEPAL; 10 mM
imidazole; 0.2 mM PMSF and 1 mM DTT). Cells were
lysed by sonication at 20 pulses at 3 min interval for 25
times (Branson Sonifier 450). The bacterial lysate was cen-
trifuged at 16,000 rpm for 30 min at 4°C to remove cell
debris. The lysate was stored frozen at -70°C until subse-
quent protein purification.
Purification of the Tat protein
We used two different chromatography techniques,
Nickel-NTA and SP-Sepharose, in tandem to purify Tat
from bacterial cell lysate. The protein fraction eluted from
the Ni-NTA columns was directly loaded to the SP-Sepha-
rose column without delay and without removing imida-
zole. DTT at a concentration of 1 mM was included in all
the reagents to minimize oxidation of Tat. All the materi-
als that came in contact with Tat were siliconized to min-
imize protein loss by adherence to surfaces. Protein
solutions were kept in dark to avoid photo-inactivation of
Tat. The scheme for Tat purification is depicted in figure-
2. A column (# 732-1010, BioRad, Hercules, CA) was
packed with 2 ml of Ni-NTA beads (#70666, Novagen,
Madison, MI) following the manufacturer's instructions
and equilibrated with the lysis buffer. The bacterial cell
lysate was repeatedly passed through the column at least
four times to ensure protein binding. The column was
washed thoroughly with 40 bed volumes of the wash
buffer, (2% Triton X-100; 20 mM Tris-HCl, pH 7.9; 10%
glycerol; 0.4 mM EDTA; 30 mM KCl; 0.1% IGEPAL; 50
mM imidazole; 0.2 mM PMSF and 1 mM DTT). Triton X-
100, at 2% concentration, removed the bulk of endotoxin
efficiently (Table-1). The washing procedure was repeated
four additional times with the same buffer without Triton
X-100. An additional wash with 0.5 M NaCl in phosphate
buffer (pH 7.4) was used to remove proteins bound non-
specifically. Column-bound protein was eluted by passing
5 ml of the elution buffer (300 mM imidazole and 1 mM
DTT in 50 mM phosphate buffer, pH 6.4). Eluted protein
was collected in 1 ml aliquots for analysis or forwarded
for the subsequent ion-exchange chromatography. While
most of the E. coli proteins have a positive isoelectric
point, HIV-1 Tat proteins are negatively charged (pI values
of B- and C-Tat proteins used here are 9.56 and 8.80,
respectively). We exploited the differences in the overall
charge of Tat and the E. coli proteins and used an anion-
exchange chromatography to remove traces of the host
proteins from the preparations. One ml of the SP Sepha-
rose fast flow Ion exchanger resin (#17-0729-10, Amer-
sham Biosciences, Uppsala) was packaged into a column
following the manufacturer's instructions. The column
was equilibrated with 50 mM phosphate buffer. The pro-
tein eluted from the Ni-NTA column was directly applied
to the SP Sepharose column. The column was washed four
times with phosphate buffer containing 2% Triton X-100
and 1 mM DTT to remove any residual endotoxins that
may have copurified in the first step of purification. Wash-
ing was repeated for four additional times with phosphate
buffer without Triton X-100. Finally a single wash with 0.2
M NaCl in 20 mM Tris buffer (pH 8.0) was used to remove
proteins bound nonspecifically. Bound Tat was eluted
with 2.5 ml of elution buffer (0.5 M NaCl and 1 mM DTT
in 20 mM Tris buffer, pH 8.0) and the eluted protein was
collected in 5 aliquots of 0.5 ml each. The aliquots were
immediately lyophilized and stored at -70°C until
required.
Western blot analysis of Tat
Recombinant Tat protein was boiled for 5 min in the gel
loading buffer (250 mM Tris-HCl, pH 6.8, with 4% SDS,
20% glycerol, 0.01% bromophenol blue and 10% β-mer-
captoethanol), resolved on a 15% SDS-PAGE gel and
transferred to an Immobilon-P membrane (# IPVH00010,
Millipore, Massachusetts). The membrane was blocked
with 3% BSA and probed with a Tat-specific monoclonal
antibody (# 4138, NIH AIDS Research and Reference Rea-
gent Program), diluted 1:1,000 in PBS, at room tempera-
ture for 2 h. Membranes were washed and incubated with
a secondary antibody conjugated to horseradish peroxi-
dase. The blot was developed by incubating the mem-
brane in the substrate solution containing 3 μl/ml H2O2
and 0.5 mg/ml 3,3'-diaminobenzidine tetrahydrochloride
(Sigma) in PBS.
Estimation of the endotoxin
Levels of endotoxin in the protein solutions were assessed
using a commercial kit (QCL-1000, Biowhittaker, Walk-
ersville, MD, USA) following manufacturer's instructions.
Briefly, 50 μl of the samples or the endotoxin standards (a
series of four two-fold dilutions) and blank containing
endotoxin quality water were dispensed into duplicate
wells of a microtiter plate pre-equilibrated at 37°C. ToRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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each well 50 μl of LAL reagent were added, contents mixed
and plate incubated at 37°C for 10 min. This was fol-
lowed by the addition of 100 μl of substrate solution to
each well and additional incubation for 6 min at 37°C.
The reaction was stopped by adding 100 μl of the stop rea-
gent and the optical density was read at 405 nm. The con-
centration of endotoxin in the protein samples was
evaluated by regression analysis.
Mass spectrometry and circular dichroism measurments of 
C-Tat
Tat protein was dialyzed against water for 12 h and mixed
with 1 μl of the matrix, prepared by adding 0.05% trifluor-
oacetic acid to a saturated solution of sinapinic acid (3,5-
dimethoxy-4-hydroxycinnamic acid), and spotted onto
the MALDI Plate. After the spot dried completely, it was
excited with laser shots and the mass of the C-Tat was
determined using MALDI mass spectrometry, on the Ultra
Flex TOF/MALDI-TOF mass spectrometer (Bruker Dalton-
ics, Billerica, MA). CD spectra were measured with 0.1 cm
path length from 250-190 nm on a Jasco-810 spectropo-
larimeter. CD spectra were averaged for 2 or 3 accumula-
tions. The samples were prepared in 10 mM phosphate
buffer (pH 7.0) and the protein concentration was 225
μg/ml.
DTNB assay for determining the free sulfhydryl content of 
C-Tat
10 ng of Tat protein incubated for 60 days at different tem-
peratures (room temperature, 4°C, -20°C and -70°C) was
mixed with 0.1 mM 5, 5'-dithiobis (2-nitrobenzoic acid)
(DTNB) in 10 mM phosphate buffer at pH 8.0. After incu-
bation for 20 min at room temperature, the absorbance at
412 nm was measured.
Preparation of the human primary monocytes
Monocytes were isolated from fresh peripheral blood
using a two-step density gradient strategy essentially as
described previously [71]. Briefly, fresh blood was col-
lected from healthy donors using vacuutainers containing
EDTA (Becton Dickinson, Franklin). Blood was diluted by
adding three volumes of PBS and overlayed above Ficol-
Hypaque (1.077 g/ml, H8889, Sigma). The samples were
centrifuged at 1,100 RPM for 30 min at room tempera-
ture. Peripheral blood mononuclear cells were retrieved
from the interface and subjected to an additional round of
density gradient centrifugation using percoll (1.064 g/
ml,17-0891-01, Amersham Biosciences, Uppsala). The
cells were centrifuged at 1,500 rpm for 30 min, recovered
from the interface and washed 3 or 4 times with PBS. The
monocytes were found to be approximately 86% pure by
flow cytometry (Figure 5A, in set) using anti- human
CD14- monoclonal antibody conjugated to PE (BD
Pharmingen). The cell staining, fixing and flow cytometry
protocols are described below. THP-1 and U373MG cells
were maintained in RPMI and DMEM, respectively
(Sigma) each supplemented with 10% fetal calf serum
(Gibco-BRL, Gaithersburg, MD), penicillin (100 U/ml),
streptomycin (100 mg/ml), and L- glutamine (2 mM).
Transactivation assays for Tat
HEK293 cells were transfected with pLTR-GFP and treated
with the Tat protein. Alternatively, HEK293 cells were
cotransfected with the GFP reporter plasmid and a Tat-
expression vector. CEM-GFP cells (# 3655, NIH AIDS
Research and Reference Reagent Program) contain a GFP
expression cassette under the control of subtype-B LTR.
CEM-GFP cells were transfected with 5 μg/ml of Tat for-
mulated in the Bioporter protein transfection reagent
(Gene Therapy Systems, San Diego, USA). Twenty-four,
48 or 72 hours after the transfection, cells were harvested
by scrapping (HEK293) or centrifugation (CEM-GFP)
washed once with phosphate-buffered saline, resus-
pended in 500 μl of 1 mM EDTA in PBS, and fixed in for-
maldehyde at a final concentration of 2%. The cells were
analyzed with a FACSCalibur flow cytometer (Becton
Dickenson, San Jose, CA, USA) and the data analysis was
performed using CellQuest Pro software. The live cells
were gated on the basis of forward and side scatter. The
number of GFP positive cells was determined by using
scattergram of side scatter versus FL-1. Cells with fluores-
cence intensity greater than 101 were considered to be GFP
positive and the gating was done accordingly. A total of
10, 000 events were scored. HLM-1 cells harboring an
integrated virus defective for Tat produce large quantities
of p24 if complemented for Tat defect. HLM-1 cells in 6-
well culture plates were incubated with 5 μg/ml of recom-
binant Tat for 2 h in serum-free medium following which
the medium was replaced by complete medium. Culture
supernatant was sampled every 24 h. Empigen was added
to each sample to a final concentration of 0.1%, and the
samples were incubated at 56°C for 30 min to inactivate
the virus and to release the p24 antigen. The quantity of
p24 in the samples was measured using a commercial kit
following manufacturer's instructions (Perkin Elmer life
sciences, Boston, MA). Alkaline phosphatase secreted into
the culture medium was quantified using a colorimetric
assay as described previously [95]. In all transfections, we
used CMV-β-galactosidase reporter vector as an internal
standard for normalization. β-galactosidase activity in cell
extracts was measured using a colorimetric assay [96].
Evaluation of cytokine induction by Tat
Using primary monocytes, THP-1 and U373MG cell lines,
we evaluated expression of two different cytokines, TNF-α
and IL-6, after the cells were exposed to recombinant Tat
proteins. Expression of TNF-α from monocytes was mon-
itored 24 h after Tat exposure using a commercial kit
(R&D Systems, Minneapolis, MN). Total RNA was iso-
lated using Trizol reagent from U373MG cells with orRetrovirology 2006, 3:53 http://www.retrovirology.com/content/3/1/53
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without Tat exposure and first strand cDNA was prepared
from total cellular RNA using random primers. PCR was
performed using published primers for IL-6 and β-actin
[97]. β-actin primers served as internal controls.
Upregulation of chemokine-receptor expression on 
monocytes by Tat
Freshly isolated monocytes (5 × 105) were stimulated with
100 ng/ml B- or C-Tat proteins or left without Tat treat-
ment. Cells were harvested 72 h following Tat-treatment,
resuspended in 100 μl of PBS, incubated for 20 min with
PE conjugated monoclonal antibodies to human CXCR4
(12G5; Pharmingen, San Diego, California, USA) or
CCR5 (2D7; Pharmingen). Cells were washed once with
phosphate-buffered saline, resuspended in 500 μl of 1
mM EDTA in PBS, and fixed in formaldehyde at a final
concentration of 2%. The cells were analyzed with a FAC-
SCalibur flow cytometer (Becton Dickenson, San Jose, CA,
USA) and the data analysis was performed using Cel-
lQuest Pro software. The live cells were gated on the basis
of forward and side scatter. The flow cytometry data acqui-
sition and analysis was carried out as mentioned above.
Unstained monocytes were used as control and the
expression of the chemokine receptors was analyzed using
histograms with FL-2 on the x-axis and counts on the y-
axis. A total of 10,000 events were scored.
Enzyme-linked immunosorbent assay for Tat and gp41
A total of 200 peripheral blood samples were collected
from HIV-seropositive volunteers (119 men, mean age
32.4 years, range 17–54; 40 women, mean age 29.76
years, range 20–56; 15 subjects below 15 years of age; in
the rest details were not recorded). Study subjects, repre-
senting a heterogeneous community of social and demo-
graphic groups, were voluntary participants under the care
of several government hospitals, private clinics, and refer-
ral centres dedicated to the service of HIV/AIDS, in the
southern states of Karnataka, Tamil Nadu, Andhra
Pradesh and Kerala. Most of the blood samples were col-
lected over a period of 4 years (2001–2004), after
informed consent, in EDTA vaccutainers (Beckton Dickin-
son, San Diego, CA, USA) from individuals who were
identified to be HIV seropositive by multiple enzyme-
linked immunosorbent assays and/or Western blots. The
seronegative samples were collected from healthy donors
from The Rotary Blood Bank, Bangalore. The Institutional
Bioethics Committee of JNCASR and the Institutional
Bioethics Committees at other participating institutions
approved the study to evaluate humoral immune
responses in the donor sera. The clinical profiles of all the
subjects were described previously [98]. Plasma was sepa-
rated by centrifugation and collected in 500 μl aliquots
and stored frozen. Using an indirect ELISA format, we
determined antigen-reactive IgG antibody titers to Tat and
gp41 in the plasma samples collected from 200 seroposi-
tive and 150 seronegative donors. While the Tat-ELISA
was developed in-house, a commercial kit (XCyton, Ban-
galore, India) was used for gp41 following the manufac-
turer's instructions. U-bottom micro titer wells (Greiner,
Frickenhausen, Germany) were coated with 400 ng of Tat
in 50 mM carbonate buffer (pH 9.6) and incubated at
37°C for 2 h. The wells were blocked with 3% BSA in PBS
at 37°C for 1 h. Patient sera diluted 1:100 in 5% sheep
serum containing 0.2% Tween 20 were added to appropri-
ate wells and the strips incubated at 37°C for 1 h. The
wells were washed five times with the wash buffer (50 mM
Tris, pH 8.0; 100 mM NaCl; 0.2% Tween 20). Goat anti-
human IgG antibody conjugated to Horse-radish peroxi-
dase (Calbiochem, San Diego, CA) was diluted 1:10,000,
added to each well and the strips were incubated at 37°C
for 1 h. After thorough washing, 100 μl of substrate solu-
tion (0.1 M citrate monohydrate, 0.2 M disodium hydro-
gen phosphate, 1 mg/ml OPD and 0.3% hydrogen
peroxide) was added to each well and the strips were incu-
bated in dark at room temperature for 15 min. Enzyme
reaction was stopped by adding 100 μl of 1 N HCl to each
well. The absorbance was recorded at 495 nm using an
ELISA reader (Molecular Devices, Sunnyvale, CA).
Statistical methods
All the statistical analyses were performed with the SPSS
package. Experiments were performed two or three times,
and values obtained from three replicate samples were
averaged in each experiment. Data are presented as mean
value with the standard deviation (± 1 S. D.). Statistical
significance was tested using Student's paired t-test. Differ-
ences were considered significant at P < 0.05.
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